![Frontiers | PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome Frontiers | PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome](https://www.frontiersin.org/files/Articles/273409/fphar-08-00561-HTML/image_m/fphar-08-00561-g001.jpg)
Frontiers | PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer
![Frontiers | Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: Current status and future directions Frontiers | Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: Current status and future directions](https://www.frontiersin.org/files/Articles/1044904/fopht-02-1044904-HTML/image_m/fopht-02-1044904-g001.jpg)
Frontiers | Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: Current status and future directions
![Merck receives EC approval for Keytruda to treat relapsed Hodgkin Lymphoma - Pharmaceutical Technology Merck receives EC approval for Keytruda to treat relapsed Hodgkin Lymphoma - Pharmaceutical Technology](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2017/09/main-1249.jpg)
Merck receives EC approval for Keytruda to treat relapsed Hodgkin Lymphoma - Pharmaceutical Technology
![Frontiers | Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations Frontiers | Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations](https://www.frontiersin.org/files/Articles/330851/fonc-08-00086-HTML/image_m/fonc-08-00086-g001.jpg)
Frontiers | Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
![FDA Approves Merck's KEYTRUDA® (Pembrolizumab) for First-Line Treatment of Patients with Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer, First Single-Agent, Anti-PD-1 Therapy Approved for the First-Line Treatment of These Patients - FDA Approves Merck's KEYTRUDA® (Pembrolizumab) for First-Line Treatment of Patients with Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer, First Single-Agent, Anti-PD-1 Therapy Approved for the First-Line Treatment of These Patients -](https://www.empr.com/wp-content/uploads/sites/7/2018/12/72d6c8c6fdce4a30af70a0ebc78a1feb-Keytruda-monogr.png)
FDA Approves Merck's KEYTRUDA® (Pembrolizumab) for First-Line Treatment of Patients with Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer, First Single-Agent, Anti-PD-1 Therapy Approved for the First-Line Treatment of These Patients -
![Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater | Journal of Clinical Oncology Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2019/jco.2019.37.issue-7/jco.18.00149/20190216/images/large/jco.18.00149t1.jpeg)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater | Journal of Clinical Oncology
![Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial - The Lancet Healthy Longevity Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial - The Lancet Healthy Longevity](https://www.thelancet.com/cms/attachment/7a7d5d3a-428b-4293-bccb-2be588c11397/gr1.gif)
Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial - The Lancet Healthy Longevity
![Cancers | Free Full-Text | Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines Cancers | Free Full-Text | Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines](https://pub.mdpi-res.com/cancers/cancers-13-01296/article_deploy/html/images/cancers-13-01296-ag-550.jpg?1615856731)
Cancers | Free Full-Text | Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines
![Zinc complex of 3,5-di-tert-butyl salicylate inhibits viability, migration, and invasion in triple-negative breast cancer cells | Scientific Reports Zinc complex of 3,5-di-tert-butyl salicylate inhibits viability, migration, and invasion in triple-negative breast cancer cells | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-08704-0/MediaObjects/41598_2022_8704_Fig1_HTML.png)